1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Carbajo, R.J. Mora, P. Sanchez del Pino, M.M. Perez-Paya, E. Pineda-Lucena, A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 4 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking US Proteins PSFGEY 0867 1097-0134 71 1670 1685 10.1002/prot.21854 18076077 Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach. 2008 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 3813.342 CELLULAR TUMOR ANTIGEN P53 TETRAMERIZATION DOMAIN, RESIDUES 326-356 YES 4 syn polymer TUMOR SUPPRESSOR P53, PHOSPHOPROTEIN P53, ANTIGEN NY-CO-13, P53 no no EYFFLKIRGRERFEMFRELNEALELKDAQAG EYFFLKIRGRERFEMFRELNEALELKDAQAG A,B,C,D polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n citation citation_author pdbx_nmr_spectrometer repository Initial release Version format compliance Version format compliance Data collection Database references 1 0 2007-08-28 1 1 2011-05-08 1 2 2011-07-13 1 3 2018-04-25 _citation.journal_id_ISSN _citation.page_last _citation.pdbx_database_id_DOI _citation.title _citation_author.name _pdbx_nmr_spectrometer.model SOLUTION STRUCTURE DETERMINATION OF A P53 MUTANT DIMERIZATION DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE P53 TETRAMERIZATION DOMAIN CRYSTAL STRUCTURE CRYSTAL STRUCTURE OF P53 TETRAMERIZATION DOMAIN SOLUTION STRUCTURE OF THE C-TERMINAL NEGATIVE REGULATORY DOMAIN OF P53 IN A COMPLEX WITH CA2+-BOUND S100B(BB) CRYSTAL STRUCTURE OF THE BRCT DOMAINS OF HUMAN 53BP1 BOUND TO THE P53 TUMOR SUPRESSOR CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 NMR SOLUTION STRUCTURE OF DESIGNED P53 DIMER NMR STRUCTURE OF CBP BROMODOMAIN IN COMPLEX WITH P53 PEPTIDE CRYSTAL STRUCTURE OF THE 53BP1 BRCT REGION COMPLEXED TOTUMOR SUPPRESSOR P53 STRUCTURE OF A SIR2 ENZYME BOUND TO AN ACETYLATED P53PEPTIDE P53 (OLIGOMERIZATION DOMAIN) (NMR, MINIMIZED AVERAGE STRUCTURE) P53 (OLIGOMERIZATION DOMAIN) (NMR, 35 STRUCTURES) TUMOR ANTIGEN P53 (TETRAMERIZATION DOMAIN) ( P53TET) (NMR, MINIMIZED AVERAGE STRUCTURE) TUMOR ANTIGEN P53 (TETRAMERIZATION DOMAIN) ( P53TET) (NMR, 19 STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES) HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES) P53 CORE DOMAIN IN COMPLEX WITH DEOXYRIBONUCLEIC ACID TUMOR SUPPRESSOR P53 COMPLEXED WITH DEOXYRIBONUCLEIC ACID CRYSTAL STRUCTURE OF THE HUMAN P53 CORE DOMAIN MUTANT M133L/V203A/N239Y/N268D AT 1 .9 A RESOLUTION. CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF THEMETHYLTRANSFERASE SET9 (ALSO KNOWN AS SET7 /9) WITH A P53PEPTIDE AND SAH XENOPUS LAEVIS MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF HUMAN P53 MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 P53-53BP2 COMPLEX STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX I) STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX IV) STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX III) STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX II) P53N (FRAGMENT 33-60) BOUND TO RPA70N HUMAN P53 CORE DOMAIN MUTANT M133L-V203A- N239Y-N268D-R273H HUMAN P53 CORE DOMAIN MUTANT M133L-H168R- V203A-N239Y-N268D HUMAN P53 CORE DOMAIN MUTANT M133L-V203A- N239Y-R249S-N268D HUMAN P53 CORE DOMAIN MUTANT M133L-H168R- V203A-N239Y-R249S-N268D HUMAN P53 CORE DOMAIN MUTANT T123A-M133L- H168R-V203A-N239Y-R249S-N268D CRYSTAL STRUCTURE OF THE TRAF-LIKE DOMAIN OF HAUSP/USP7BOUND TO A P53 PEPTIDE SOLUTION STRUCTURE OF HUMAN P53 DNA BINDING DOMAIN. P53 TETRAMERIZATION DOMAIN WILD TYPE P53 TETRAMERIZATION DOMAIN MUTANT Y327S T329G Q331G HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES) HELIX DETERMINATION METHOD: AUTHOR PROVIDED. PDBE Y PDBE 2006-08-08 REL CHEMICAL SYNTHESIS 9606 HUMAN HOMO SAPIENS sample ENGINEERED RESIDUE IN CHAIN A, THR 329 TO PHE ENGINEERED RESIDUE IN CHAIN A, GLN 331 TO LYS ENGINEERED RESIDUE IN CHAIN B, THR 329 TO PHE ENGINEERED RESIDUE IN CHAIN B, GLN 331 TO LYS ENGINEERED RESIDUE IN CHAIN C, THR 329 TO PHE ENGINEERED RESIDUE IN CHAIN C, GLN 331 TO LYS ENGINEERED RESIDUE IN CHAIN D, THR 329 TO PHE ENGINEERED RESIDUE IN CHAIN D, GLN 331 TO LYS NONE TOTAL ENERGY 30 30 NOESY TOCSY 7.2 pH 1.0 atm 300.0 K CNS 5 5% D2O/95% WATER BRUNGER,ADAMS,CLORE,DELANO,GROS, GROSSE- KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU,READ, RICE,SIMONSON,WARREN refinement CNS structure solution SPARKY 600 Bruker AMX GLU 326 n 1 GLU 326 A TYR 327 n 2 TYR 327 A PHE 328 n 3 PHE 328 A PHE 329 n 4 PHE 329 A LEU 330 n 5 LEU 330 A LYS 331 n 6 LYS 331 A ILE 332 n 7 ILE 332 A ARG 333 n 8 ARG 333 A GLY 334 n 9 GLY 334 A ARG 335 n 10 ARG 335 A GLU 336 n 11 GLU 336 A ARG 337 n 12 ARG 337 A PHE 338 n 13 PHE 338 A GLU 339 n 14 GLU 339 A MET 340 n 15 MET 340 A PHE 341 n 16 PHE 341 A ARG 342 n 17 ARG 342 A GLU 343 n 18 GLU 343 A LEU 344 n 19 LEU 344 A ASN 345 n 20 ASN 345 A GLU 346 n 21 GLU 346 A ALA 347 n 22 ALA 347 A LEU 348 n 23 LEU 348 A GLU 349 n 24 GLU 349 A LEU 350 n 25 LEU 350 A LYS 351 n 26 LYS 351 A ASP 352 n 27 ASP 352 A ALA 353 n 28 ALA 353 A GLN 354 n 29 GLN 354 A ALA 355 n 30 ALA 355 A GLY 356 n 31 GLY 356 A GLU 326 n 1 GLU 326 B TYR 327 n 2 TYR 327 B PHE 328 n 3 PHE 328 B PHE 329 n 4 PHE 329 B LEU 330 n 5 LEU 330 B LYS 331 n 6 LYS 331 B ILE 332 n 7 ILE 332 B ARG 333 n 8 ARG 333 B GLY 334 n 9 GLY 334 B ARG 335 n 10 ARG 335 B GLU 336 n 11 GLU 336 B ARG 337 n 12 ARG 337 B PHE 338 n 13 PHE 338 B GLU 339 n 14 GLU 339 B MET 340 n 15 MET 340 B PHE 341 n 16 PHE 341 B ARG 342 n 17 ARG 342 B GLU 343 n 18 GLU 343 B LEU 344 n 19 LEU 344 B ASN 345 n 20 ASN 345 B GLU 346 n 21 GLU 346 B ALA 347 n 22 ALA 347 B LEU 348 n 23 LEU 348 B GLU 349 n 24 GLU 349 B LEU 350 n 25 LEU 350 B LYS 351 n 26 LYS 351 B ASP 352 n 27 ASP 352 B ALA 353 n 28 ALA 353 B GLN 354 n 29 GLN 354 B ALA 355 n 30 ALA 355 B GLY 356 n 31 GLY 356 B GLU 326 n 1 GLU 326 C TYR 327 n 2 TYR 327 C PHE 328 n 3 PHE 328 C PHE 329 n 4 PHE 329 C LEU 330 n 5 LEU 330 C LYS 331 n 6 LYS 331 C ILE 332 n 7 ILE 332 C ARG 333 n 8 ARG 333 C GLY 334 n 9 GLY 334 C ARG 335 n 10 ARG 335 C GLU 336 n 11 GLU 336 C ARG 337 n 12 ARG 337 C PHE 338 n 13 PHE 338 C GLU 339 n 14 GLU 339 C MET 340 n 15 MET 340 C PHE 341 n 16 PHE 341 C ARG 342 n 17 ARG 342 C GLU 343 n 18 GLU 343 C LEU 344 n 19 LEU 344 C ASN 345 n 20 ASN 345 C GLU 346 n 21 GLU 346 C ALA 347 n 22 ALA 347 C LEU 348 n 23 LEU 348 C GLU 349 n 24 GLU 349 C LEU 350 n 25 LEU 350 C LYS 351 n 26 LYS 351 C ASP 352 n 27 ASP 352 C ALA 353 n 28 ALA 353 C GLN 354 n 29 GLN 354 C ALA 355 n 30 ALA 355 C GLY 356 n 31 GLY 356 C GLU 326 n 1 GLU 326 D TYR 327 n 2 TYR 327 D PHE 328 n 3 PHE 328 D PHE 329 n 4 PHE 329 D LEU 330 n 5 LEU 330 D LYS 331 n 6 LYS 331 D ILE 332 n 7 ILE 332 D ARG 333 n 8 ARG 333 D GLY 334 n 9 GLY 334 D ARG 335 n 10 ARG 335 D GLU 336 n 11 GLU 336 D ARG 337 n 12 ARG 337 D PHE 338 n 13 PHE 338 D GLU 339 n 14 GLU 339 D MET 340 n 15 MET 340 D PHE 341 n 16 PHE 341 D ARG 342 n 17 ARG 342 D GLU 343 n 18 GLU 343 D LEU 344 n 19 LEU 344 D ASN 345 n 20 ASN 345 D GLU 346 n 21 GLU 346 D ALA 347 n 22 ALA 347 D LEU 348 n 23 LEU 348 D GLU 349 n 24 GLU 349 D LEU 350 n 25 LEU 350 D LYS 351 n 26 LYS 351 D ASP 352 n 27 ASP 352 D ALA 353 n 28 ALA 353 D GLN 354 n 29 GLN 354 D ALA 355 n 30 ALA 355 D GLY 356 n 31 GLY 356 D author_defined_assembly 4 tetrameric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A N ILE 332 A N ILE 7 B O PHE 328 B O PHE 3 C N ILE 332 C N ILE 7 D O PHE 328 D O PHE 3 1 A ALA 355 -93.46 -62.29 1 B TYR 327 61.09 112.55 1 D ARG 333 -98.31 31.38 2 A ARG 333 -100.84 77.09 2 B ARG 333 -98.65 31.29 2 B ALA 355 -68.01 -72.55 2 C ARG 333 -98.50 30.92 2 D TYR 327 60.69 111.10 2 D ALA 355 -100.61 -63.02 3 A TYR 327 60.84 110.60 3 B TYR 327 60.10 106.76 3 C ARG 333 -98.47 34.26 3 C ALA 355 -100.60 -67.29 4 B ARG 333 -97.43 37.23 4 D ARG 333 -98.30 35.64 5 A ARG 333 -98.51 31.12 5 B TYR 327 60.76 111.29 5 C TYR 327 62.06 150.68 5 C LYS 331 -67.57 97.28 5 C ARG 333 -92.36 48.86 5 D TYR 327 60.21 106.96 5 D ARG 333 -98.63 31.09 6 A PHE 328 -151.39 89.48 6 C ARG 333 -98.36 33.86 6 D TYR 327 60.72 111.23 7 A TYR 327 61.13 112.64 7 A ARG 333 -98.59 33.36 7 B LEU 330 -164.41 104.85 7 B ARG 333 -98.53 32.65 7 C TYR 327 60.62 84.33 8 A ARG 333 -98.71 31.12 8 C TYR 327 63.29 123.30 8 D TYR 327 59.98 106.50 8 D ARG 333 -104.78 74.90 9 A TYR 327 60.42 97.46 9 A ALA 355 -123.17 -57.49 9 B TYR 327 60.37 103.80 9 B ARG 333 -93.53 47.52 9 C TYR 327 61.16 112.77 9 C ARG 333 -98.29 33.60 9 D TYR 327 60.51 110.90 10 B TYR 327 60.88 111.76 10 B ARG 333 -92.94 48.04 10 B ALA 355 -103.69 -69.39 10 C TYR 327 62.84 120.26 10 C ALA 355 -105.22 -68.81 10 D ARG 333 -99.69 34.35 11 A TYR 327 61.40 113.81 11 B TYR 327 61.45 116.79 11 C TYR 327 63.16 123.04 11 C ARG 333 -98.78 30.95 11 D TYR 327 63.71 137.17 11 D ARG 333 -95.84 42.44 12 A ARG 333 -98.60 31.11 12 B TYR 327 61.17 112.68 12 B ARG 333 -98.65 32.40 12 C LYS 331 -68.06 84.06 12 C ARG 333 -98.35 35.60 12 D ARG 333 -98.57 31.85 12 D ALA 355 -98.40 35.11 13 A TYR 327 61.35 113.78 13 A ARG 333 -97.45 37.77 13 B TYR 327 60.33 96.89 13 C TYR 327 60.41 104.01 13 D TYR 327 60.85 111.91 14 A TYR 327 61.14 112.42 14 B TYR 327 60.78 111.07 14 B LYS 331 -66.85 83.67 14 C TYR 327 61.36 113.65 14 C ARG 333 -103.53 76.80 14 D LEU 330 -161.77 107.32 14 D ARG 333 -98.66 35.40 15 A LEU 330 -161.62 118.49 15 B ARG 333 -98.60 32.50 15 B ALA 355 -98.75 33.50 15 C TYR 327 60.70 111.70 16 B TYR 327 60.50 97.56 16 B LYS 331 -66.43 84.94 16 B ALA 355 -61.58 -75.14 16 C ARG 333 -105.95 74.80 16 D TYR 327 60.38 110.40 17 C TYR 327 60.30 109.69 17 C LYS 331 -66.54 83.47 17 C ALA 355 -97.86 34.93 18 A TYR 327 60.68 111.49 18 B TYR 327 60.26 101.96 18 B ARG 333 -98.40 33.26 18 C TYR 327 60.53 110.72 18 C ARG 333 -90.94 51.20 18 C ALA 355 -97.16 38.18 19 A TYR 327 61.59 114.37 19 B TYR 327 63.27 127.89 19 C TYR 327 60.89 111.76 19 D TYR 327 60.71 111.33 20 A TYR 327 -171.17 105.72 20 A ARG 333 -95.59 42.13 20 B ARG 333 -92.37 48.87 20 C ARG 333 -98.68 31.30 20 D ARG 333 -94.51 44.54 21 A ALA 355 -89.95 -71.16 21 B LEU 330 -164.95 118.22 21 B ARG 333 -98.67 31.32 21 C ARG 333 -98.53 30.63 21 C ALA 355 -175.21 36.80 21 D ARG 333 -96.83 39.42 22 A TYR 327 63.27 141.49 22 B TYR 327 60.27 89.17 22 B ARG 333 -98.52 33.58 22 D ARG 333 -99.13 31.60 23 A TYR 327 60.67 111.12 23 A ARG 333 -98.62 33.02 23 B TYR 327 62.51 147.86 23 C ARG 333 -98.54 33.68 23 C ALA 355 -98.63 32.82 23 D TYR 327 60.59 111.31 24 B TYR 327 61.64 153.04 24 B ARG 333 -105.94 72.95 24 C ALA 355 -96.17 -68.17 24 D TYR 327 61.04 112.39 24 D ARG 333 -98.26 31.71 24 D ALA 355 -98.10 36.64 25 B TYR 327 60.29 108.71 25 B ARG 333 -98.54 31.30 25 D TYR 327 60.45 100.40 26 B ARG 333 -100.25 78.31 26 C TYR 327 60.91 111.65 26 C LEU 330 -165.00 118.40 26 D TYR 327 63.30 139.79 26 D ALA 355 -92.32 -60.24 27 A TYR 327 60.65 111.13 27 B TYR 327 60.17 106.17 27 B LEU 330 -160.03 103.08 27 B ALA 355 -102.09 -66.66 27 C TYR 327 60.78 111.56 27 C ARG 333 -99.29 31.06 27 C ALA 355 -97.56 36.96 28 A ARG 333 -109.93 74.59 28 A ALA 355 -85.81 -71.43 28 B TYR 327 60.55 106.42 29 A TYR 327 61.46 114.05 29 A ARG 333 -98.69 32.48 29 B ARG 333 -98.90 31.30 29 C LEU 330 -170.92 124.38 29 D TYR 327 60.77 111.47 29 D ARG 333 -108.00 72.21 30 B TYR 327 62.91 144.59 30 B ARG 333 -98.89 31.24 30 C ARG 333 -98.82 31.57 CELLULAR TUMOR ANTIGEN P53 p53 tetramerization domain mutant T329F Q331K 1 N N 1 N N 1 N N 1 N N A ARG 335 A ARG 10 HELX_P A ALA 355 A ALA 30 1 1 21 B ARG 335 B ARG 10 HELX_P B ALA 355 B ALA 30 1 2 21 C ARG 335 C ARG 10 HELX_P C ALA 355 C ALA 30 1 3 21 D ARG 335 D ARG 10 HELX_P D ALA 355 D ALA 30 1 4 21 TRANSCRIPTION P53, ZINC, ACTIVATOR, APOPTOSIS, WILD TYPE, CELL CYCLE, ACETYLATION, DNA-BINDING, POLYMORPHISM, TETRAMERIZATION DOMAIN, TRANSCRIPTION REGULATION, ANTI-ONCOGENE, NUCLEAR PROTEIN, PHOSPHORYLATION, LI-FRAUMENI SYNDROME, HOST-VIRUS INTERACTION, DISEASE MUTATION, ALTERNATIVE SPLICING, GLYCOPROTEIN, TRANSCRIPTION, METAL-BINDING P53_HUMAN UNP 1 P04637 326 356 2J10 326 356 P04637 A 1 1 31 326 356 2J10 326 356 P04637 B 1 1 31 326 356 2J10 326 356 P04637 C 1 1 31 326 356 2J10 326 356 P04637 D 1 1 31 1 THR engineered mutation PHE 329 2J10 A P04637 UNP 329 4 1 GLN engineered mutation LYS 331 2J10 A P04637 UNP 331 6 2 THR engineered mutation PHE 329 2J10 B P04637 UNP 329 4 2 GLN engineered mutation LYS 331 2J10 B P04637 UNP 331 6 3 THR engineered mutation PHE 329 2J10 C P04637 UNP 329 4 3 GLN engineered mutation LYS 331 2J10 C P04637 UNP 331 6 4 THR engineered mutation PHE 329 2J10 D P04637 UNP 329 4 4 GLN engineered mutation LYS 331 2J10 D P04637 UNP 331 6 2 2 anti-parallel anti-parallel A PHE 328 A PHE 3 A ILE 332 A ILE 7 B PHE 328 B PHE 3 B ILE 332 B ILE 7 C PHE 328 C PHE 3 C ARG 333 C ARG 8 D TYR 327 D TYR 2 D ILE 332 D ILE 7 1 P 1